Accelerating global access to life-saving vaccines.

We apply rigorous science to build knowledge and support for the value of vaccines.

Updates

IVAC’s VIRA Chatbot Receives Silver Anthem Award for Innovative Approach to Vaccine Communication

March 2023

COVID-19 vaccine uptake has plateaued globally, largely in part due to rampant misinformation about the vaccine’s safety and effectiveness. To combat this phenomenon, IVAC launched VIRA, the COVID-19 vaccine chatbot, at the peak of the pandemic in July 2021. VIRA was developed in partnership with IBM Research with the goal of providing evidence-based, credible, and […]

IVAC Economics & Finance Team Highlights Immunization Financing Gap

February 2023

IVAC health economists, led by Bryan Patenaude, ScD, have recently published several papers focusing on the cost of procuring and delivering life-saving vaccines to increase coverage and meet Immunization Agenda 2030 (IA 2030) targets. Despite the sizable global investment in immunization programs over the past few decades, a considerable gap remains between the funding available […]

IVAC engages with Jordan on introduction of the Pneumococcal Conjugate Vaccine (PCV) – a life-saving vaccine for children

January 2023

Pneumonia continues to be the number one infectious killer of young children globally. In the World Health Organization (WHO)’s Eastern Mediterranean (EMRO) region, each year an estimated 923,000 children under 5 years of age (U5) die, with pneumonia accounting for over 20% of deaths among this age group (UNICEF, 2022). PCV protects against infections caused […]